Rockwell Medical, Inc. (RMTI) is a leading end-stage renal disease (ESRD) and chronic kidney disease (CKD) therapy and drug development company. Established in 1996 and based in the US, the company focuses on providing innovative products and services for the treatment of iron-deficiency, secondary hyperparathyroidism, and hemodialysis. Rockwell Medical was listed on NASDAQ under the ticker symbol "RMTI" and has remained instrumental in propagating the mission of improving the quality of life for kidney disease patients.
Rockwell Medical's primary products include Triferic, Calcitriol (Active Vitamin D) Injection, and Hemodialysis concentrates. Triferic is the sole FDA-approved therapy indicated in replacing iron and maintaining hemoglobin in hemodialysis patients experiencing chronic kidney disease. Calcitriol, an active Vitamin D injection, is used for management of hypocalcemia in patients undergoing maintenance hemodialysis or suffering from secondary hyperparathyroidism. Hemodialysis concentrates encompass a broad range of products exclusively designed for patients undergoing dialysis treatment.
In addition, Rockwell has dedicated extensive efforts to research and development with the aim of creating new patents that form the foundation for future product offerings. Its comprehensive R&D approach ensures the realization of breakthrough technologies, enhancing the management of CKD and improving patients' lives.
The company's manufacturing practices adhere strictly to the standards set by the Food and Drug Administration (FDA) to ensure product safety and efficacy. Its products are distributed both domestically and exported worldwide, including continents like Europe and Asia.
Rockwell Medical’s partnerships and collaborations have played a significant role in the growth and international recognition of the company. It has collaborated with global healthcare giants to widen the reach and accessibility of its products. The company exhibits a growth strategy driven by natural expansion into new markets, acquisitions, alliances, and innovation.
Corporate social responsibility is a significant aspect of the company's ethos. Rockwell has demonstrated commitment towards the community through uninhibited access to its medical treatments and compliance with environmentally friendly practices. Consequently, it has received numerous accolades for its patient-focused approach and pioneering efforts in nephrology.
Rockwell Medical has consistently evolved and thrived through its unwavering commitment to changing the face of kidney disease treatment. With its unique product portfolio and dedication to improving patient lives, the company continues to blaze trails in the medical field.